Skip to content
value.today
AIT Therapeutics, Inc. logo

AIT Therapeutics, Inc.

🇮🇱 Rehovot, Israel, IsraelPharmaceuticalsFounded 2015
Total raised
$10 M
1 round on record
Latest round
$10 M
Feb 2018
First round on record
Feb 2018
Today
Went public
See the company page

AIT Therapeutics, Inc. is listed today as Beyond Air, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of AIT Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2024$21 MPrivate placement after listing$10 to $50 million

AIT Therapeutics, Inc.: Private sale, Sep 2024

Investors in this round

15 investors had bought by the notice of Oct 11, 2024: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,442,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas Quinton Larson · Executive Officer · Chief Financial Officer
  • Michael A. Gaul · Executive Officer · Chief Operating Officer
  • Steven A. Lisi · Executive Officer, Director · Chairman and CEO
  • Erick P. Lucera · Director
  • Robert A. Carey · Director
  • Ron A. Bentsur · Director
  • William P. Forbes · Director
  • Yoori P. Lee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) LTD (CRD 119037) · London, United KingdomSold in IL, NY
  • JONESTRADING INSTITUTIONAL SERVICES LLC (CRD 6888) · Thousand Oaks, CaliforniaSold in CT, FL, MA, NY, UT
  • Brookline Capital Markets, a division of Arcadia Securities, LLC (CRD 44656) · New York, New YorkSold in NY
  • BTIG, LLC (CRD 122225) · San Francisco, CaliforniaSold in MD, NJ, NY

Signed by Douglas Quinton Larson, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 11, 2024. Read the notice at the SEC.

equity, optionsSEC
Jun 2023$1 MPrivate placement after listingUnder $2 million

AIT Therapeutics, Inc.: Private sale, Jun 2023

Investors in this round

2 investors had bought by the notice of Jun 28, 2023: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amir Quinton Avniel · Executive Officer, Director · Chief Business Officer
  • Douglas Quinton Larson · Executive Officer · Chief Financial Officer
  • Jeff Lynn Myers · Executive Officer · Chief Medical Officer
  • Michael A. Gaul · Executive Officer · Chief Operating Officer
  • Steven A. Lisi · Executive Officer, Director · Chairman and CEO
  • Erick P Lucera · Director
  • Robert Lynn Carey · Director
  • Ron Lynn Bentsur · Director
  • William P Forbes · Director
  • Yoori P Lee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Douglas Quinton Larson, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 28, 2023. Read the notice at the SEC.

equity, optionsSEC
Jun 2019$8 MPrivate placement after listing$2 to $10 million

AIT Therapeutics, Inc.: Private sale, Jun 2019

Investors in this round

47 investors had bought by the notice of Jun 18, 2019: 47 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Avniel Amir · Executive Officer, Director · President and Chief Operating Officer
  • Beck Douglas · Executive Officer · Chief Financial Officer
  • Steven Lisi · Executive Officer, Director · Chairman and CEO
  • Bentsur Ron · Director
  • Carey Robert · Director
  • Forbes William · Director
  • Lee Yoori · Director
  • Lucera Erick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “Chairman and CEO”

Signed by Steven Lisi, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 18, 2019. Read the notice at the SEC.

equitySEC
Feb 2018$10 MNo. 1$2 to $10 million

AIT Therapeutics, Inc.: Raise no. 1, Feb 2018

Investors in this round

58 investors had bought by the notice of Mar 1, 2018: 58 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$687,411
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amir A. Avniel · Director, Executive Officer
  • Hai A. Aviv · Executive Officer
  • Steven A. Lisi · Executive Officer, Director
  • Ari J. Raved · Director
  • David A. Grossman · Director
  • Erick J. Lucera · Director
  • Ron A. Bentsur · Director
  • Yoori J. Lee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in CA, CO, CT, FL, MA, MD, NJ, WI
  • Brookline Capital Markets (CRD 120852) · Centennial, ColoradoSold in CA, CO, CT, FL, MA, MD, NJ, WI

Signed by Steven A. Lisi, CEO and Chairman of the Board of Directors. Source: SEC Form D, newest notice filed Mar 1, 2018. Read the notice at the SEC.

optionsSEC
Jan 2017$37 MIssued in a merger or acquisition$10 to $50 million

AIT Therapeutics, Inc.: Private sale, Jan 2017

Investors in this round

58 investors had bought by the notice of Jan 31, 2017: 43 accredited, 15 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$37 M of $37 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amir Avniel · Executive Officer, Director
  • Racheli Vizman · Executive Officer
  • Ari Raved · Director
  • David Grossman · Director
  • Jerome B. Zeldis · Director
  • Ron Bentsur · Director
  • Steven A. Lisi · Director
  • Yossef Av-Gay · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering amount derived from value of Advanced Inhalation Therapies (AIT) Ltd Ordinary Shares cancelled in exchange for shares of Issuer's common stock. The common stock was issued in a share exchange transaction with no additional consideration.”
  • On the use of proceeds: “No new proceeds received in share exchange transaction.”
  • On a merger: “Shares of common stock issued in exchange for the cancellation of equity of Advanced Inhalation Therapies (AIT) Ltd. upon closing of a reverse merger transaction with such entity.”

Signed by Amir Avniel, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 31, 2017. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • AIT Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2024).

    SEC Form D · Oct 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2024

That is all the official record says: AIT Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of AIT Therapeutics, Inc. are on record.

Investors#

No investor of AIT Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 58 investors.

Largest shareholders today

Institutions holding Beyond Air, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by AIT Therapeutics, Inc.
NameRoleNamed in
Douglas Quinton LarsonChief Financial OfficerOct 2024
Michael A. GaulChief Operating OfficerOct 2024
Steven A. LisiChairman and CEOOct 2024
Amir Quinton AvnielChief Business OfficerJun 2023
Jeff Lynn MyersChief Medical OfficerJun 2023
Avniel AmirPresident and Chief Operating OfficerJun 2019
Beck DouglasChief Financial OfficerJun 2019
Steven LisiChairman and CEOJun 2019
Amir A. AvnielExecutive officerMar 2018
Hai A. AvivExecutive officerMar 2018
Amir AvnielExecutive officerJan 2017
Racheli VizmanExecutive officerJan 2017
Erick P. LuceraDirectorOct 2024
Robert A. CareyDirectorOct 2024
Ron A. BentsurDirectorOct 2024
Steven A. LisiChairman and CEOOct 2024
William P. ForbesDirectorOct 2024
Yoori P. LeeDirectorOct 2024
Amir Quinton AvnielChief Business OfficerJun 2023
Erick P LuceraDirectorJun 2023
Robert Lynn CareyDirectorJun 2023
Ron Lynn BentsurDirectorJun 2023
William P ForbesDirectorJun 2023
Yoori P LeeDirectorJun 2023
Avniel AmirPresident and Chief Operating OfficerJun 2019
Bentsur RonDirectorJun 2019
Carey RobertDirectorJun 2019
Forbes WilliamDirectorJun 2019
Lee YooriDirectorJun 2019
Lucera ErickDirectorJun 2019
Steven LisiChairman and CEOJun 2019
Amir A. AvnielDirectorMar 2018
Ari J. RavedDirectorMar 2018
David A. GrossmanDirectorMar 2018
Erick J. LuceraDirectorMar 2018
Yoori J. LeeDirectorMar 2018
Amir AvnielDirectorJan 2017
Ari RavedDirectorJan 2017
David GrossmanDirectorJan 2017
Jerome B. ZeldisDirectorJan 2017

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.